To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular ...

Nucleoside reverse transcriptase inhibitors -- antiretroviral drugs approved to treat HIV and hepatitis B -- were associated ...

Groundbreaking gene therapy offers hope for a boy with fatal muscular dystrophy, potentially slowing disease progression and ...

From STAT’s Adam Feuerstein: The FDA informed Capricor Therapeutics that a meeting of outside experts will be convened to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy ...

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients ...

Duchenne muscular dystrophy (DMD) in India faces challenges in diagnosis, treatment, and support, highlighting the urgent ...